Organization (Industry)
Nanjing IASO Biotechnology Co., Ltd.
ClinicalTrials.gov lists Nanjing IASO Biotechnology Co., Ltd. as lead sponsor of 12 trials. It has 21 active development programs and 5 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 4 registered with a 2026 start date. The dashed outline is the pace from the 4 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Nanjing IASO Biotechnology Co., Ltd.: 12 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (28)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Multiple Myeloma | 8 |
| Lupus Erythematosus, Systemic | 4 |
| Recurrence | 3 |
| Leukemia, Plasma Cell | 2 |
| Lupus Nephritis | 2 |
Showing 5 of 28 disease areas.
Trials by start year as sponsor or collaborator (7)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 5 |
| 2024 | 3 |
| 2023 | 2 |
| 2022 | 5 |
| 2021 | 2 |
| 2020 | 2 |
Prediction, not a registry value: median of 30 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; 3 of 6 predicted trials reach the 36-month horizon. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (21)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| DEXAMETHASONE | Multiple Myeloma | Phase 3 | 1 |
| DARATUMUMAB | Multiple Myeloma | Phase 3 | 1 |
| BORTEZOMIB | Multiple Myeloma | Phase 3 | 1 |
| Equecabtagene Autoleucel Injection | Multiple Myeloma | Phase 3 | 1 |
| POMALIDOMIDE | Multiple Myeloma | Phase 3 | 1 |
Showing 5 of 21 active programs.
Approved assets (5)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| DARATUMUMAB | 1 |
| BORTEZOMIB | 1 |
| DEXAMETHASONE | 1 |
| POMALIDOMIDE | 1 |
| Sirolimus | 1 |
Journals published in (6)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Blood | 1 |
| British journal of haematology | 1 |
| Cell | 1 |
| Frontiers in immunology | 1 |
| Med (New York, N.Y.) | 1 |
Showing 5 of 6 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 3 | 2 | 2025-10-21 |
Organization relationships (2)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Chunrui Li | Co sponsors trial with | 1 |
| The First Affiliated Hospital with Nanjing Medical University | Co sponsors trial with | 1 |
Latest dated events (26)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-26 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-25 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-11-21 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 26 events.
Biomarker capability evidence (188)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABCD1 | Trial collaborator | Named in trial inclusion criteria |
| ALK | Trial collaborator | Named in trial inclusion criteria |
| AQP4 | Trial collaborator | Named in trial inclusion criteria |
| BTK | Trial collaborator | Named in trial inclusion criteria |
| CD38 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 188 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sponsor delivery record, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.